Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AGX PET for Evaluation of Vorasidenib Response in Low-grade IDH-Mutant Glioma
NCT07469735Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of 18F-AGX in Diffuse Glioma (DG), sponsored by Huashan Hospital. Primary endpoint: Change in Tumor Metabolic Activity Assessed by 18F-AGX PET at 12 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
18F-AGX
03
Conditions
Diffuse Glioma (DG)
Beyond the preview
Go deeper on NCT07469735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469735.